BRAF and melanoma: In this way, pharmacological inhibition of AURKA by MLN8237 (alisertib) resulted in the reduction of melanoma cell proliferation and induced senescence and apoptosis in cells with BRAF and NRAS mutation, and in vemurafenib (BRAF inhibitor) resistant cells [54].